RIFT

Rift Therapeutics is a biotechnology company focused on developing first-in-class therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. The company's lead program, RTX-001, is a monoclonal antibody that targets complement component 5a (C5a), a potent mediator of inflammation. By selectively inhibiting C5a, Rift aims to address a variety of chronic inflammatory conditions while minimizing off-target effects on the broader immune system. Headquartered in San Diego, the company leverages its expertise in antibody engineering and complement biology to advance its pipeline of novel biologics. Rift is backed by prominent life science investors, including Xontogeny and Breakout Ventures.